Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin sulfonated human - KM Biologics/Teijin

Drug Profile

Immune globulin sulfonated human - KM Biologics/Teijin

Alternative Names: Dried sulfonated human immunoglobulin - KM Biologics/Teijin; Freeze-dried sulfonated human immunoglobulin; GGS-CIDP; GGS-MMN; GGS-MPA; GGS-ON; IVIG - KM Biologics/Teijin; KD-371; KD5-71; KD6-71; Sulfonated human immunoglobulin; Venilon

Latest Information Update: 07 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kaketsuken; Teijin
  • Developer Kaketsuken; KM Biologics; Teijin
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Microscopic polyangiitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Churg-Strauss syndrome; Infections; Optic neuritis
  • Preregistration Motor neuron disease
  • Phase III Microscopic polyangiitis
  • Discontinued Idiopathic pulmonary fibrosis; Multiple sclerosis

Most Recent Events

  • 19 Mar 2020 Discontinued - Clinical-Phase-Unknown for Idiopathic pulmonary fibrosis in Japan (IV)
  • 06 Feb 2020 Preregistration for Motor neuron disease in Japan (IV) (Meiji Holdings pipeline, February 2020)
  • 08 Jul 2019 Preregistration for Chronic inflammatory demyelinating polyradiculoneuropathy in Japan (IV) (Teijin Pharma pipeline July 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top